Top

Published in:

Open Access 01-12-2012 | Review

Mammalian target of rapamycin signaling in diabetic cardiovascular disease

Authors: Zhao Zhong Chong, Kenneth Maiese

Published in: Cardiovascular Diabetology | Issue 1/2012

Abstract

Diabetes mellitus currently affects more than 170 million individuals worldwide and is expected to afflict another 200 million individuals in the next 30 years. Complications of diabetes as a result of oxidant stress affect multiple systems throughout the body, but involvement of the cardiovascular system may be one of the most severe in light of the impact upon cardiac and vascular function that can result in rapid morbidity and mortality for individuals. Given these concerns, the signaling pathways of the mammalian target of rapamycin (mTOR) offer exciting prospects for the development of novel therapies for the cardiovascular complications of diabetes. In the cardiovascular and metabolic systems, mTOR and its multi-protein complexes of TORC1 and TORC2 regulate insulin release and signaling, endothelial cell survival and growth, cardiomyocyte proliferation, resistance to β-cell injury, and cell longevity. Yet, mTOR can, at times, alter insulin signaling and lead to insulin resistance in the cardiovascular system during diabetes mellitus. It is therefore vital to understand the complex relationship mTOR and its downstream pathways hold during metabolic disease in order to develop novel strategies for the complications of diabetes mellitus in the cardiovascular system.

Available only for authorised users

Chong ZZ, Shang YC, Zhang L, Wang S, Maiese K: Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev. 2010, 3: 374-391. 10.4161/oxim.3.6.14787.PubMedCentralPubMed

Heitman J, Movva NR, Hall MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991, 253: 905-909. 10.1126/science.1715094.PubMed

Weber JD, Gutmann DH: Deconvoluting mTOR biology. Cell Cycle. 2012, 11: 236-248. 10.4161/cc.11.2.19022.PubMedCentralPubMed

Hwang SK, Kim HH: The functions of mTOR in ischemic diseases. BMB Rep. 2011, 44: 506-511. 10.5483/BMBRep.2011.44.8.506.PubMed

Abraham RT: mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol. 2004, 279: 299-319. 10.1007/978-3-642-18930-2_18.PubMed

Ekim B, Magnuson B, Acosta-Jaquez HA, Keller JA, Feener EP, Fingar DC: mTOR Kinase Domain Phosphorylation Promotes mTORC1 Signaling, Cell Growth, and Cell Cycle Progression. Mol Cell Biol. 2011, 31: 2787-2801. 10.1128/MCB.05437-11.PubMedCentralPubMed

Soliman GA, Acosta-Jaquez HA, Dunlop EA, Ekim B, Maj NE, Tee AR, Fingar DC: mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action. J Biol Chem. 2010, 285: 7866-7879. 10.1074/jbc.M109.096222.PubMedCentralPubMed

Reynolds THt, Bodine SC, Lawrence JC: Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load. J Biol Chem. 2002, 277: 17657-17662. 10.1074/jbc.M201142200.PubMed

Scott PH, Brunn GJ, Kohn AD, Roth RA, Lawrence JC: Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc Natl Acad Sci U S A. 1998, 95: 7772-7777. 10.1073/pnas.95.13.7772.PubMedCentralPubMed

10.

Takahashi T, Hara K, Inoue H, Kawa Y, Tokunaga C, Hidayat S, Yoshino K, Kuroda Y, Yonezawa K: Carboxyl-terminal region conserved among phosphoinositide-kinase-related kinases is indispensable for mTOR function in vivo and in vitro. Genes Cells. 2000, 5: 765-775. 10.1046/j.1365-2443.2000.00365.x.PubMed

11.

Chen J, Zheng XF, Brown EJ, Schreiber SL: Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. Proc Natl Acad Sci U S A. 1995, 92: 4947-4951. 10.1073/pnas.92.11.4947.PubMedCentralPubMed

12.

Takahara T, Hara K, Yonezawa K, Sorimachi H, Maeda T: Nutrient-dependent multimerization of the mammalian target of rapamycin through the N-terminal HEAT repeat region. J Biol Chem. 2006, 281: 28605-28614. 10.1074/jbc.M606087200.PubMed

13.

Acosta-Jaquez HA, Keller JA, Foster KG, Ekim B, Soliman GA, Feener EP, Ballif BA, Fingar DC: Site-specific mTOR phosphorylation promotes mTORC1-mediated signaling and cell growth. Mol Cell Biol. 2009, 29: 4308-4324. 10.1128/MCB.01665-08.PubMedCentralPubMed

14.

Martin DE, Hall MN: The expanding TOR signaling network. Curr Opin Cell Biol. 2005, 17: 158-166. 10.1016/j.ceb.2005.02.008.PubMed

15.

Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002, 110: 163-175. 10.1016/S0092-8674(02)00808-5.PubMed

16.

Benjamin D, Colombi M, Moroni C, Hall MN: Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov. 2011, 10: 868-880. 10.1038/nrd3531.PubMed

17.

Wang H, Zhang Q, Wen Q, Zheng Y, Philip L, Jiang H, Lin J, Zheng W: Proline-rich Akt substrate of 40 kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal. 2012, 24: 17-24. 10.1016/j.cellsig.2011.08.010.PubMed

18.

Wang L, Harris TE, Roth RA, Lawrence JC: PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem. 2007, 282: 20036-20044. 10.1074/jbc.M702376200.PubMed

19.

Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM: PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007, 25: 903-915. 10.1016/j.molcel.2007.03.003.PubMed

20.

Guertin DA, Stevens DM, Thoreen CC, Burds AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ, Sabatini DM: Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell. 2006, 11: 859-871. 10.1016/j.devcel.2006.10.007.PubMed

21.

Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS: Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science. 2012, 335: 1638-1643. 10.1126/science.1215135.PubMedCentralPubMed

22.

Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009, 137: 873-886. 10.1016/j.cell.2009.03.046.PubMedCentralPubMed

23.

Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, Tokunaga C, Avruch J, Yonezawa K: Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002, 110: 177-189. 10.1016/S0092-8674(02)00833-4.PubMed

24.

Jastrzebski K, Hannan KM, Tchoubrieva EB, Hannan RD, Pearson RB: Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors. 2007, 25: 209-226. 10.1080/08977190701779101.PubMed

25.

Bhandari BK, Feliers D, Duraisamy S, Stewart JL, Gingras AC, Abboud HE, Choudhury GG, Sonenberg N, Kasinath BS: Insulin regulation of protein translation repressor 4E-BP1, an eIF4E-binding protein, in renal epithelial cells. Kidney Int. 2001, 59: 866-875. 10.1046/j.1523-1755.2001.059003866.x.PubMed

26.

Jacinto E, Loewith R, Schmidt A, Lin S, Ruegg MA, Hall A, Hall MN: Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 2004, 6: 1122-1128. 10.1038/ncb1183.PubMed

27.

Rosner M, Fuchs C, Siegel N, Valli A, Hengstschlager M: Functional interaction of mammalian target of rapamycin complexes in regulating mammalian cell size and cell cycle. Hum Mol Genet. 2009, 18: 3298-3310. 10.1093/hmg/ddp271.PubMedCentralPubMed

28.

Dada S, Demartines N, Dormond O: mTORC2 regulates PGE2-mediated endothelial cell survival and migration. Biochem Biophys Res Commun. 2008, 372: 875-879. 10.1016/j.bbrc.2008.05.154.PubMed

29.

Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JC: Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol. 2008, 28: 61-70. 10.1128/MCB.01405-07.PubMedCentralPubMed

30.

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005, 307: 1098-1101. 10.1126/science.1106148.PubMed

31.

Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM: mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol. 2006, 16: 1865-1870. 10.1016/j.cub.2006.08.001.PubMed

32.

Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B: SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006, 127: 125-137. 10.1016/j.cell.2006.08.033.PubMed

33.

Chen CH, Sarbassov DD: The mTOR (mammalian target of rapamycin) kinase maintains integrity of mTOR complex 2. J Biol Chem. 2011, 286: 40386-40394. 10.1074/jbc.M111.282590.PubMedCentralPubMed

34.

Pearce LR, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M, Ibrahim AF, Gourlay R, Magnuson MA, Alessi DR: Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J. 2007, 405: 513-522. 10.1042/BJ20070540.PubMedCentralPubMed

35.

Pearce LR, Sommer EM, Sakamoto K, Wullschleger S, Alessi DR: Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney. Biochem J. 2011, 436: 169-179. 10.1042/BJ20102103.PubMed

36.

Hernandez-Negrete I, Carretero-Ortega J, Rosenfeldt H, Hernandez-Garcia R, Calderon-Salinas JV, Reyes-Cruz G, Gutkind JS, Vazquez-Prado J: P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J Biol Chem. 2007, 282: 23708-23715. 10.1074/jbc.M703771200.PubMed

37.

Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM: Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004, 14: 1296-1302. 10.1016/j.cub.2004.06.054.PubMed

38.

Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, Lee EY, Weiss HL, O'Connor KL, Gao T, Evers BM: mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011, 71: 3246-3256. 10.1158/0008-5472.CAN-10-4058.PubMedCentralPubMed

39.

Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB: Diabetes in Asia: epidemiology, risk factors, and pathophysiology. Jama. 2009, 301: 2129-2140. 10.1001/jama.2009.726.PubMed

40.

Maiese K, Chong ZZ, Shang YC: Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem. 2007, 14: 1729-1738.PubMedCentralPubMed

41.

Maiese K, Shang YC, Chong ZZ, Hou J: Diabetes mellitus: channeling care through cellular discovery. Curr Neurovasc Res. 2010, 7: 59-64. 10.2174/156720210790820217.PubMedCentralPubMed

42.

Melnik BC, John SM, Schmitz G: Over-stimulation of insulin/IGF-1 signaling by western diet may promote diseases of civilization: lessons learnt from laron syndrome. Nutr Metab (Lond). 2011, 8: 41-10.1186/1743-7075-8-41.

43.

Harris MI, Eastman RC: Early detection of undiagnosed diabetes mellitus: a US perspective. Diabetes Metab Res Rev. 2000, 16: 230-236. 10.1002/1520-7560(2000)9999:9999<::AID-DMRR122>3.0.CO;2-W.PubMed

44.

Kurban S, Mehmetoglu I, Yerlikaya HF, Gonen S, Erdem S: Effect of chronic regular exercise on serum ischemia-modified albumin levels and oxidative stress in type 2 diabetes mellitus. Endocr Res. 2011, 36: 116-123. 10.3109/07435800.2011.566236.PubMed

45.

Yang H, Jin X, Kei Lam CW, Yan SK: Oxidative stress and diabetes mellitus. Clin Chem Lab Med. 2011, 49: 1773-1782.PubMed

46.

Daneman D: Type 1 diabetes. Lancet. 2006, 367: 847-858. 10.1016/S0140-6736(06)68341-4.PubMed

47.

Maiese K, Chong ZZ, Shang YC, Hou J: Novel Avenues of Drug Discovery and Biomarkers for Diabetes Mellitus. J Clin Pharmacol. 2011, 51: 128-152. 10.1177/0091270010362904.PubMedCentralPubMed

48.

Kernan WN, Inzucchi SE, Viscoli CM, Brass LM, Bravata DM, Horwitz RI: Insulin resistance and risk for stroke. Neurology. 2002, 59: 809-815. 10.1212/WNL.59.6.809.PubMed

49.

Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY, Smithline Kinder L, Ellis D, Becker DJ: Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2003, 26: 1374-1379. 10.2337/diacare.26.5.1374.PubMed

50.

Maiese K, Chong ZZ, Shang YC, Hou J: FoxO proteins: cunning concepts and considerations for the cardiovascular system. Clin Sci (Lond). 2009, 116: 191-203. 10.1042/CS20080113.

51.

Reagan LP: Diabetes as a chronic metabolic stressor: causes, consequences and clinical complications. Exp Neurol. 2012, 233: 68-78. 10.1016/j.expneurol.2011.02.004.PubMedCentralPubMed

52.

Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, Reinecke M: Mechanisms of beta-cell death in type 2 diabetes. Diabetes. 2005, 54 (Suppl 2): S108-113.PubMed

53.

Maiese K, Hou J, Chong ZZ, Shang YC: Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. ScientificWorldJournal. 2009, 9: 1072-1104.PubMedCentralPubMed

54.

Zengi A, Ercan G, Caglayan O, Tamsel S, Karadeniz M, Simsir I, Harman E, Kahraman C, Orman M, Cetinkalp S, Ozgen G: Increased oxidative DNA damage in lean normoglycemic offspring of type 2 diabetic patients. Exp Clin Endocrinol Diabetes. 2011, 119: 467-471. 10.1055/s-0031-1275289.PubMed

55.

Afanas'ev I: Signaling of reactive oxygen and nitrogen species in Diabetes mellitus. Oxid Med Cell Longev. 2010, 3: 361-373. 10.4161/oxim.3.6.14415.PubMedCentralPubMed

56.

Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. Jama. 2005, 293: 90-95. 10.1001/jama.293.1.90.PubMedCentralPubMed

57.

Chong ZZ, Shang YC, Maiese K: Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res. 2007, 4: 194-204.PubMedCentralPubMed

58.

Gaddini L, Villa M, Matteucci A, Mallozzi C, Petrucci TC, Di Stasi AM, Leo L, Malchiodi-Albedi F, Pricci F: Early effects of high glucose in retinal tissue cultures Renin-Angiotensin system-dependent and -independent signaling. Neurobiol Dis. 2009, 35: 278-285. 10.1016/j.nbd.2009.05.013.PubMed

59.

Hou J, Chong ZZ, Shang YC, Maiese K: FoxO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrinol. 2010, 321: 194-206. 10.1016/j.mce.2010.02.037.PubMedCentralPubMed

60.

Gossai D, Lau-Cam CA: The effects of taurine, taurine homologs and hypotaurine on cell and membrane antioxidative system alterations caused by type 2 diabetes in rat erythrocytes. Adv Exp Med Biol. 2009, 643: 359-368. 10.1007/978-0-387-75681-3_37.PubMed

61.

Singh DK, Winocour P, Farrington K: Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol. 2008, 4: 216-226. 10.1038/ncpneph0757.PubMed

62.

Barbosa NB, Oliveira C, Araldi D, Folmer V, Rocha JB, Nogueira CW: Acute diphenyl diselenide treatment reduces hyperglycemia but does not change delta-aminolevulinate dehydratase activity in alloxan-induced diabetes in rats. Biol Pharm Bull. 2008, 31: 2200-2204. 10.1248/bpb.31.2200.PubMed

63.

Maiese K, Chong ZZ, Shang YC: OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med. 2008, 14: 219-227. 10.1016/j.molmed.2008.03.002.PubMedCentralPubMed

64.

Chong ZZ, Hou J, Shang YC, Wang S, Maiese K: EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a, GSK-3beta, and beta-Catenin to Foster Vascular Integrity During Experimental Diabetes. Curr Neurovasc Res. 2011, 8: 103-120. 10.2174/156720211795495402.PubMedCentralPubMed

65.

Hou J, Chong ZZ, Shang YC, Maiese K: Early apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation. Curr Neurovasc Res. 2010, 7: 95-112. 10.2174/156720210791184899.PubMedCentralPubMed

66.

Szabo C: Role of nitrosative stress in the pathogenesis of diabetic vascular dysfunction. Br J Pharmacol. 2009, 156: 713-727. 10.1111/j.1476-5381.2008.00086.x.PubMedCentralPubMed

67.

Ceriello A, dello Russo P, Amstad P, Cerutti P: High glucose induces antioxidant enzymes in human endothelial cells in culture. Evidence linking hyperglycemia and oxidative stress. Diabetes. 1996, 45: 471-477. 10.2337/diabetes.45.4.471.PubMed

68.

Valle I, Alvarez-Barrientos A, Arza E, Lamas S, Monsalve M: PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res. 2005, 66: 562-573. 10.1016/j.cardiores.2005.01.026.PubMed

69.

Chong ZZ, Kang JQ, Maiese K: Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002, 106: 2973-2979. 10.1161/01.CIR.0000039103.58920.1F.PubMed

70.

Li Y, Wu H, Khardori R, Song YH, Lu YW, Geng YJ: Insulin-like growth factor-1 receptor activation prevents high glucose-induced mitochondrial dysfunction, cytochrome-c release and apoptosis. Biochem Biophys Res Commun. 2009, 384: 259-264. 10.1016/j.bbrc.2009.04.113.PubMed

71.

Alexandru N, Popov D, Georgescu A: Platelet dysfunction in vascular pathologies and how can it be treated. Thromb Res. 2012, 129: 116-126. 10.1016/j.thromres.2011.09.026.PubMed

72.

Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM: Diabetes and mortality following acute coronary syndromes. JAMA. 2007, 298: 765-775. 10.1001/jama.298.7.765.PubMed

73.

Thackeray JT, Radziuk J, Harper ME, Suuronen EJ, Ascah KJ, Beanlands RS, Dasilva JN: Sympathetic nervous dysregulation in the absence of systolic left ventricular dysfunction in a rat model of insulin resistance with hyperglycemia. Cardiovasc Diabetol. 2011, 10: 75-10.1186/1475-2840-10-75.PubMedCentralPubMed

74.

Maiese K, Chong ZZ, Hou J, Shang YC: The vitamin nicotinamide: translating nutrition into clinical care. Molecules. 2009, 14: 3446-3485. 10.3390/molecules14093446.PubMedCentralPubMed

75.

Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006, 295: 1681-1687. 10.1001/jama.295.14.1681.PubMed

76.

Estep PW, Warner JB, Bulyk ML: Short-term calorie restriction in male mice feminizes gene expression and alters key regulators of conserved aging regulatory pathways. PLoS One. 2009, 4: e5242-10.1371/journal.pone.0005242.PubMedCentralPubMed

77.

Chong ZZ, Shang YC, Wang S, Maiese K: SIRT1: New avenues of discovery for disorders of oxidative stress. Expert opinion on therapeutic targets. 2012, 16: 167-178. 10.1517/14728222.2012.648926.PubMedCentralPubMed

78.

Herranz D, Serrano M: SIRT1: recent lessons from mouse models. Nat Rev Cancer. 2010, 10: 819-823. 10.1038/nrc2962.PubMedCentralPubMed

79.

Kelly GS: A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev. 2010, 15: 313-328.PubMed

80.

Maiese K, Chong ZZ, Shang YC, Wang S: Translating cell survival and cell longevity into treatment strategies with SIRT1. Rom J Morphol Embryol. 2011, 52: 1173-1185.PubMedCentralPubMed

81.

Orimo M, Minamino T, Miyauchi H, Tateno K, Okada S, Moriya J, Komuro I: Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol. 2009, 29: 889-894. 10.1161/ATVBAHA.109.185694.PubMed

82.

Zhang QJ, Wang Z, Chen HZ, Zhou S, Zheng W, Liu G, Wei YS, Cai H, Liu DP, Liang CC: Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res. 2008, 80: 191-199. 10.1093/cvr/cvn224.PubMedCentralPubMed

83.

Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S, Shimamoto K, Horio Y: Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem. 2010, 285: 8375-8382. 10.1074/jbc.M109.090266.PubMedCentralPubMed

84.

Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isono M, Isshiki K, Uzu T, Kashiwagi A, Koya D: Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med. 2006, 40: 2175-2182. 10.1016/j.freeradbiomed.2006.02.014.PubMed

85.

Hou J, Wang S, Shang YC, Chong ZZ, Maiese K: Erythropoietin Employs Cell Longevity Pathways of SIRT1 to Foster Endothelial Vascular Integrity During Oxidant Stress. Curr Neurovasc Res. 2011, 8: 220-235. 10.2174/156720211796558069.PubMedCentralPubMed

86.

Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF, Sadoshima J: Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res. 2007, 100: 1512-1521. 10.1161/01.RES.0000267723.65696.4a.PubMed

87.

Wang RH, Kim HS, Xiao C, Xu X, Gavrilova O, Deng CX: Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J Clin Invest. 2011, 121: 4477-4490. 10.1172/JCI46243.PubMedCentralPubMed

88.

Guo W, Qian L, Zhang J, Zhang W, Morrison A, Hayes P, Wilson S, Chen T, Zhao J: Sirt1 overexpression in neurons promotes neurite outgrowth and cell survival through inhibition of the mTOR signaling. J Neurosci Res. 2011, 89: 1723-1736. 10.1002/jnr.22725.PubMed

89.

Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009, 460: 392-395.PubMedCentralPubMed

90.

Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F: Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 2009, 326: 140-144. 10.1126/science.1177221.PubMed

91.

Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, Yurova MN, Antoch MP, Blagosklonny MV: Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol. 2010, 176: 2092-2097. 10.2353/ajpath.2010.091050.PubMedCentralPubMed

92.

Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel Y, Klumperman J, Thorens B, Thomas G: Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature. 2000, 408: 994-997. 10.1038/35050135.PubMed

93.

Hamada S, Hara K, Hamada T, Yasuda H, Moriyama H, Nakayama R, Nagata M, Yokono K: Upregulation of the mammalian target of rapamycin complex 1 pathway by Ras homolog enriched in brain in pancreatic beta-cells leads to increased beta-cell mass and prevention of hyperglycemia. Diabetes. 2009, 58: 1321-1332. 10.2337/db08-0519.PubMedCentralPubMed

94.

Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, Castel J, Berthault MF, Magnan C, Cerasi E, Kaiser N, Leibowitz G: mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes. 2008, 57: 945-957. 10.2337/db07-0922.PubMed

95.

Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, Caillon A, Maeder C, Fournier M, Montet X, Rohner-Jeanrenaud F, Foti M: Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol. 2011, 165: 2325-2340.

96.

Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, Barnett J, Leslie NR, Cheng S, Shepherd PR: The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol. 2004, 166: 213-223. 10.1083/jcb.200403069.PubMedCentralPubMed

97.

Khamzina L, Veilleux A, Bergeron S, Marette A: Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance. Endocrinology. 2005, 146: 1473-1481.PubMed

98.

Kim JA, Jang HJ, Martinez-Lemus LA, Sowers JR: Activation of mTOR/p70S6 Kinase by ANG II Inhibits Insulin Stimulated Endothelial Nitric Oxide Synthase and Vasodilation. Am J Physiol Endocrinol Metab. 2011, 302: E201-208.PubMedCentralPubMed

99.

Inoki K, Zhu T, Guan KL: TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003, 115: 577-590. 10.1016/S0092-8674(03)00929-2.PubMed

100.

Paiva MA, Rutter-Locher Z, Goncalves LM, Providencia LA, Davidson SM, Yellon DM, Mocanu MM: Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol. 2011, 300: H2123-2134. 10.1152/ajpheart.00707.2010.PubMedCentralPubMed

101.

Saha AK, Xu XJ, Lawson E, Deoliveira R, Brandon AE, Kraegen EW, Ruderman NB: Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes. 2010, 59: 2426-2434. 10.2337/db09-1870.PubMedCentralPubMed

102.

Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA, Cantley LC: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A. 2004, 101: 3329-3335. 10.1073/pnas.0308061100.PubMedCentralPubMed

103.

Jessen N, Koh HJ, Folmes CD, Wagg C, Fujii N, Lofgren B, Wolf CM, Berul CI, Hirshman MF, Lopaschuk GD, Goodyear LJ: Ablation of LKB1 in the heart leads to energy deprivation and impaired cardiac function. Biochim Biophys Acta. 2010, 1802: 593-600. 10.1016/j.bbadis.2010.04.008.PubMedCentralPubMed

104.

Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature. 2001, 409: 307-312. 10.1038/35053000.PubMed

105.

Kang S, Chemaly ER, Hajjar RJ, Lebeche D: Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J Biol Chem. 2011, 286: 18465-18473. 10.1074/jbc.M110.200022.PubMedCentralPubMed

106.

Shan J, Nguyen TB, Totary-Jain H, Dansky H, Marx SO, Marks AR: Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors. Proc Natl Acad Sci U S A. 2008, 105: 19006-19011. 10.1073/pnas.0809743105.PubMedCentralPubMed

107.

Pasini E, Flati V, Paiardi S, Rizzoni D, Porteri E, Aquilani R, Assanelli D, Corsetti G, Speca S, Rezzani R: Intracellular molecular effects of insulin resistance in patients with metabolic syndrome. Cardiovasc Diabetol. 2010, 9: 46-10.1186/1475-2840-9-46.PubMedCentralPubMed

108.

Medeiros C, Frederico MJ, da Luz G, Pauli JR, Silva AS, Pinho RA, Velloso LA, Ropelle ER, De Souza CT: Exercise training reduces insulin resistance and upregulates the mTOR/p70S6k pathway in cardiac muscle of diet-induced obesity rats. J Cell Physiol. 2011, 226: 666-674. 10.1002/jcp.22387.PubMed

109.

Wang B, Atherton P, Patel R, Manning G, Donnelly R: Antiangiogenic effects and transcriptional regulation of pigment epithelium-derived factor in diabetic retinopathy. Microvasc Res. 2010, 80: 31-36. 10.1016/j.mvr.2010.02.012.PubMed

110.

Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE: Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arterioscler Thromb Vasc Biol. 2009, 29: 1172-1178. 10.1161/ATVBAHA.109.185918.PubMedCentralPubMed

111.

Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O: Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer. 2010, 9: 57.PubMedCentralPubMed

112.

Chong ZZ, Li F, Maiese K: The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med. 2007, 19: 263-272.PubMedCentralPubMed

113.

Dello Russo C, Lisi L, Tringali G, Navarra P: Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem Pharmacol. 2009, 78: 1242-1251. 10.1016/j.bcp.2009.06.097.PubMed

114.

Poulose SM, Bielinski DF, Carrihill-Knoll K, Rabin BM, Shukitt-Hale B: Exposure to (16)O-Particle Radiation Causes Aging-Like Decrements in Rats through Increased Oxidative Stress, Inflammation and Loss of Autophagy. Radiat Res. 2011, 176: 761-769. 10.1667/RR2605.1.PubMed

115.

Shang YC, Chong ZZ, Wang S, Maiese K: Erythropoietin and Wnt1 Govern Pathways of mTOR, Apaf-1, and XIAP in Inflammatory Microglia. Curr Neurovasc Res. 2011, 8: 270-285. 10.2174/156720211798120990.PubMedCentralPubMed

116.

Shang YC, Chong ZZ, Wang S, Maiese K: Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY). 2012, 4: 187-201.

Title: Mammalian target of rapamycin signaling in diabetic cardiovascular disease
Authors: Zhao Zhong Chong
Kenneth Maiese
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/1475-2840-11-45

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Mammalian target of rapamycin signaling in diabetic cardiovascular disease

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Platelet hyperaggregability in high-fat fed rats: A role for intraplatelet reactive-oxygen species production

Shadow of diabetes over cardiovascular disease: comparative quantification of population-attributable all-cause and cardiovascular mortality

Glycated hemoglobin and associated risk factors in older adults

Prognostic implications of surrogate markers of atherosclerosis in low to intermediate risk patients with Type 2 Diabetes

High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: Results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS)

Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page